Host defence against disseminated Candida albicans infection and implications for antifungal immunotherapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 9, 2006, Pages 891-903

  Vonk, Alieke G ^b   Netea, Mihai G ^b   Van Der Meer, Jos W M ^b   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Nijmegen University Center for Infectious Diseases ^*

Author keywords

Candida albicans; Candidiasis; Cytokines; Immunity; Immunotherapy

Indexed keywords

ANTIFUNGAL AGENT; COMPLEMENT; FLUCONAZOLE; FUNGUS VACCINE; IMMUNOLOGICAL ADJUVANT; PATTERN RECOGNITION RECEPTOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL; CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; DRUG COMBINATION; DRUG EFFECT; ECONOMICS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; NATURAL KILLER CELL; PHAGOCYTE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COMPLEMENT SYSTEM PROTEINS; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FUNGAL VACCINES; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; INTERFERON-GAMMA, RECOMBINANT; KILLER CELLS, NATURAL; PHAGOCYTES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PATTERN RECOGNITION; TH1 CELLS; TH2 CELLS;

EID: 33749056010     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.9.891     Document Type: Review

References (137)

1. SZABO I, GUAN L, ROGERS TJ: Modulation of macrophage phagocytic activity by cell wall components of Candida albicans. Cell. Immunol. (1995) 164:182-188.
2. VAN SPRIEL AB, LEUSEN JH, VAN EGMOND M et al.: Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood (2001) 97:2478-2486. (Pubitemid 32291496)
3. BROWN GD, HERRE J, WILLIAMS DL et al.: Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. (2003) 197:1119-1124. (Pubitemid 36570067)
4. GANTNER BN, SIMMONS RM, CANAVERA SJ, AKIRA S, UNDERHILL DM: Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. (2003) 197:1107-1117. • First demonstration that the inflammatory response to Candida requires recognition of dectin-1 as a receptor in addition to the TLRs.
5. CAMBI A, GIJZEN K, DE VRIES JM et al.: The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur. J. Immunol. (2003) 33:532-538. • First report indicating that DC-SIGN is an exquisite pathogen-uptake receptor that captures not only viruses, but also fungi.
6. TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Annu. Rev. Immunol. (2003) 21:335-376. • Excellent review on TLRs.
7. TADA H, NEMOTO E, SHIMAUCHI H et al.: Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. (2002) 46:503-512. (Pubitemid 34831216)
8. NETEA MG, GOW NA, MUNRO CA et al.: Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Invest. (2006) 116:1642-1650. • First study that identifies the C. albicans PAMPs recognised by the MR and TLR4. O-linked mannosyl chains are recognised by the MR, whereas N-linked mannosyl chains are recognised by the TLR4 receptor.
9. NETEA MG, VAN DER GRAAF CA, VONK AG et al.: The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. (2002) 185:1483-1489. • First report demonstrating the role of TLRs in the host response to candidiasis.
10. JOUAULT T, IBATA-OMBETTA S, TAKEUCHI O et al.: Candida albicans phospholipomannan is sensed through toll-like receptors. J. Infect. Dis. (2003) 188:165-172. (Pubitemid 36829757)
11. VILLAMON E, ROIG P, GIL ML, GOZALBO D: Toll-like receptor 2 mediates prostaglandin E(2) production in murine peritoneal macrophages and splenocytes in response to Candida albicans. Res. Microbiol. (2005) 156:115-118. (Pubitemid 40075596)
12. SURAM S, BROWN GD, GHOSH M et al.: Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor. J. Biol. Chem. (2006) 281:5506-5514. (Pubitemid 43853011)
13. NETEA MG, SUTMULLER R, HERMANN C et al.: Toll-like receptor 2 suppresses immunity against Candida albicans through Induction of IL-10 and regulatory T cells. J. Immunol. (2004) 172:3712-3718. • First study showing that C. albicans induces immunosuppression through TLR2-derived signals that mediate IL-10 production and survival of T regulatory cells, indicating a role of TLRs in bridging innate and acquired immunity.
14. MONTAGNOLI C, BACCI A, BOZZA S et al.: B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J. Immunol. (2002) 169:6298-6308. (Pubitemid 36903477)
15. VAN DER GRAAF CA, NETEA MG, VERSCHUEREN I, VAN DER MEER JW, KULLBERG BJ: Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans blastoconidia and hyphae. Infect. Immun. (2005) 73:7458-7464. (Pubitemid 41587650)
16. GANTNER BN, SIMMONS RM, UNDERHILL DM: Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J. (2005) 24:1277-1286. (Pubitemid 40516610)
17. NETEA MG, VAN DER GRAAF C, VAN DER MEER JW, KULLBERG BJ: Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J. Leukoc. Biol. (2004) 75:749-755. (Pubitemid 38580054)
18. FILLER SG, SWERDLOFF JN, HOBBS C, LUCKETT PM: Penetration and damage of endothelial cells by Candida albicans. Infect. Immun. (1995) 63:976-983.
19. PHAN QT, FRATTI RA, PRASADARAO NV, EDWARDS JE JR, FILLER SG: N-cadherin mediates endocytosis of Candida albicans by endothelial cells. J. Biol. Chem. (2005) 280:10455-10461. (Pubitemid 40395903)
20. ZINK S, NASS T, ROSEN P, ERNST JF: Migration of the fungal pathogen Candida albicans across endothelial monolayers. Infect. Immun. (1996) 64:5085-5091. (Pubitemid 26403965)
21. PHAN QT, BELANGER PH, FILLER SG: Role of hyphal formation in interactions of Candida albicans with endothelial cells. Infect. Immun. (2000) 68:3485-3490. (Pubitemid 30340448)
22. SANCHEZ AA, JOHNSTON DA, MYERS C et al.: Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect. Immun. (2004) 72:598-601. (Pubitemid 38018223)
23. IBRAHIM AS, FILLER SG, SANGLARD D, EDWARDS JE JR, HUBE B: Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect. Immun. (1998) 66:3003-3005. (Pubitemid 28261818)
24. KLOTZ SA, MACA RD: Endothelial cell contraction increases Candida adherence to exposed extracellular matrix. Infect. Immun. (1988) 56:2495-2498. (Pubitemid 18213671)
25. KLOTZ SA, HARRISON JL, MISRA RP: Aggregated platelets enhance adherence of Candida yeasts to endothelium. J. Infect. Dis. (1989) 160:669-677. (Pubitemid 19247651)
26. YEAMAN MR, SOLDAN SS, GHANNOUM MA et al.: Resistance to platelet microbicidal protein results in increased severity of experimental Candida albicans endocarditis. Infect. Immun. (1996) 64:1379-1384. (Pubitemid 26102404)
27. FILLER SG, IBE BO, IBRAHIM AS et al.: Mechanisms by which Candida albicans induces endothelial cell prostaglandin synthesis. Infect. Immun. (1994) 62:1064-1069. (Pubitemid 24065597)
28. NOVERR MC, HUFFNAGLE GB: Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. (2004) 72:6206-6210. (Pubitemid 39425396)
29. ALEM MA, DOUGLAS LJ: Prostaglandin production during growth of Candida albicans biofilms. J. Med. Microbiol. (2005) 54:1001-1005. (Pubitemid 41566768)
30. ALEM MA, DOUGLAS LJ: Effects of aspirin and other nonsteroidal anti-inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob. Agents Chemother. (2004) 48:41-47. (Pubitemid 38040174)
31. NOVERR MC, PHARE SM, TOEWS GB, COFFEY MJ, HUFFNAGLE GB: Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. (2001) 69:2957-2963. (Pubitemid 32332188)
32. OROZCO AS, ZHOU X, FILLER SG: Mechanisms of the proinflammatory response of endothelial cells to Candida albicans infection. Infect. Immun. (2000) 68:1134-1141. (Pubitemid 30108501)
33. FILLER SG, PFUNDER AS, SPELLBERG BJ, SPELLBERG JP, EDWARDS JE JR: Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect. Immun. (1996) 64:2609-2617. (Pubitemid 26226824)
34. ADAMS DH, LLOYD AR: Chemokines: leucocyte recruitment and activation cytokines. Lancet (1997) 349:490-495. (Pubitemid 27077839)
35. BEEKHUIZEN H, VAN FURTH R: Monocyte adherence to human vascular endothelium. J. Leukoc. Biol. (1993) 54:363-378. (Pubitemid 23317706)
36. KULLBERG BJ, VAN 'T WOUT JW, POELL RJ, VAN FURTH R: Combined effect of fluconazole and recombinant human interleukin- 1 on systemic candidiasis in neutropenic mice. Antimicrob. Agents Chemother. (1992) 36:1225-1229.
37. FULURIJA A, ASHMAN RB, PAPADIMITRIOU JM: Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. Microbiology (1996) 142(Pt 12):3487-3496. (Pubitemid 27026375)
38. QIAN Q, JUTILA MA, VAN ROOIJENN, CUTLER JE: Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol. (1994) 152:5000-5008. (Pubitemid 24139094)
39. JENSEN J, WARNER T, BALISH E: The role of phagocytic cells in resistance to disseminated candidiasis in granulocytopenic mice. J. Infect. Dis. (1994) 170:900-905. (Pubitemid 24296570)
40. VAN 'T WOUT JW, LINDE I, LEIJH PC, VAN FURTH R: Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infection. Eur. J. Clin. Microbiol. Infect. Dis. (1988) 7:736-741. (Pubitemid 19017156)
41. VECCHIARELLI A, BISTONI F, CENCI E, PERITO S, CASSONE A: In-vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. Sabouraudia (1985) 23:377-387. (Pubitemid 15241573)
42. BACCARINI M, BLASI E, PUCCETTI P, BISTONI F: Phagocytic killing of Candida albicans by different murine effector cells. Sabouraudia (1983) 21:271-286.
43. VONK AG, WIELAND CW, NETEA MG, KULLBERG BJ: Phagocytosis and intracellular killing of Candida albicans blastoconidia by neutrophils and macrophages: a comparison of different microbiological test systems. J. Microbiol. Methods (2002) 49:55-62. (Pubitemid 34056553)
44. BRUMMER E, MORRISON CJ, STEVENS DA: Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect. Immun. (1985) 49:724-730. (Pubitemid 15021536)
45. FERRANTE A: Tumor necrosis factor alpha potentiates neutrophil antimicrobial activity: increased fungicidal activity against Torulopsis glabrata and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect. Immun. (1989) 57:2115-2122. (Pubitemid 19186891)
46. KULLBERG BJ, VAN 'T WOUT JW, HOOGSTRATEN C, VAN FURTH R: Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J. Infect. Dis. (1993) 168:436-443. • First report of a protective effect of recombinant IFN-γ in murine candidiasis.
47. DJEU JY, BLANCHARD DK, HALKIAS D, FRIEDMAN H: Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J. Immunol. (1986) 137:2980-2984. (Pubitemid 17177810)
48. YAMAMOTO Y, KLEIN TW, FRIEDMAN H, KIMURA S, YAMAGUCHI H: Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol. Med. Microbiol. (1993) 7:15-22. (Pubitemid 23204353)
49. SCHAFFNER A, DAVIS CE, SCHAFFNER T et al.: In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J. Clin. Invest. (1986) 78:511-524. (Pubitemid 16074089)
50. ROILIDES E, HOLMES A, BLAKE C, PIZZO PA, WALSH TJ: Effects of granulocyte colony-stimulating factor and interferon- gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J. Leukoc. Biol. (1995) 57:651-656.
51. DIAMOND RD, LYMAN CA, WYSONG DR: Disparate effects of interferon-gamma and tumor necrosis factor- alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J. Clin. Invest. (1991) 87:711-720.
52. DIAMOND RD, KRZESICKI R, JAO W: Damage to pseudohyphal forms of Candida albicans by neutrophils in the absence of serum in vitro. J. Clin. Invest. (1978) 61:349-359. (Pubitemid 8280405)
53. DIAMOND RD, KRZESICKI R: Mechansims of attachment of neutrophils to Candida albicans pseudohyphae in the absence of serum, and of subsequent damage to pseudohyphae by microbicidal processes of neutrophils in vitro. J. Clin. Invest. (1978) 61:360-369. (Pubitemid 8280406)
54. DIAMOND RD, CLARK RA, HAUDENSCHILD CC: Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J. Clin. Invest. (1980) 66:908-917. (Pubitemid 11233789)
55. LEHRER RI, CLINE MJ: Interaction of Candida albicans with human leukocytes and serum. J. Bacteriol. (1969) 98:996-1004.
56. ASHMAN RB, PAPADIMITRIOU JM: Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol. Rev. (1995) 59:646-672.
57. DIAMOND RD, HAUDENSCHILD CC: Monocyte-mediated serum-independent damage to hyphal and pseudohyphal forms of Candida albicans in vitro. J. Clin. Invest. (1981) 67:173-182. (Pubitemid 11163170)
58. VAZQUEZ-TORRES A, BALISH E: Macrophages in resistance to candidiasis. Microbiol. Mol. Biol. Rev. (1997) 61:170-192. (Pubitemid 27283799)
59. FANG FC: Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. (1997) 99:2818-2825.
60. MARODI L, FOREHAND JR, JOHNSTON RB JR: Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J. Immunol. (1991) 146:2790-2794.
61. PRYOR WA, SQUADRITO GL: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. (1995) 268:L699-L722.
62. NETEA MG, MEER JW, VERSCHUEREN I, KULLBERG BJ: CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur. J. Immunol. (2002) 32:1455-1463. (Pubitemid 34546274)
63. VAZQUEZ-TORRES A, JONES-CARSON J, WARNER T, BALISH E: Nitric oxide enhances resistance of SCID mice to mucosal candidiasis. J. Infect. Dis. (1995) 172:192-198.
64. VAZQUEZ-TORRES A, JONES-CARSON J, BALISH E: Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect. Immun. (1996) 64:3127-3133. (Pubitemid 26256155)
65. ARATANI Y, KOYAMA H, NYUI S et al.: Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect. Immun. (1999) 67:1828-1836. (Pubitemid 29144403)
66. REEVES EP, LU H, JACOBS HL et al.: Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature (2002) 416:291-297. (Pubitemid 34260237)
67. MARKART P, FAUST N, GRAF T et al.: Comparison of the microbicidal and muramidase activities of mouse lysozyme M and P. Biochem. J. (2004) 380:385-392. (Pubitemid 38788109)
68. LUPETTI A, DANESI R, VAN 'T WOUT JW et al.: Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert. Opin. Investig. Drugs (2002) 11:309-318. (Pubitemid 34144874)
69. NETEA MG, GIJZEN K, COOLEN N et al.: Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes. Infect. (2004) 6:985-989. (Pubitemid 39166039)
70. D'OSTIANI CF, DEL SERO G, BACCI A et al.: Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J. Exp. Med. (2000) 191:1661-1674. (Pubitemid 30331565)
71. ROMANI L, BISTONI F, PUCCETTI P: Fungi, dendritic cells and receptors: a host perspective of fungal virulence. Trends Microbiol. (2002) 10:508-514. (Pubitemid 35284797)
72. FORSYTH CB, MATHEWS HL: Lymphocytes utilize CD11b/CD18 for adhesion to Candida albicans. Cell. Immunol. (1996) 170:91-100. (Pubitemid 26179898)
73. BENO DW, STOVER AG, MATHEWS HL: Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes. J. Immunol. (1995) 154:5273-5281.
74. ARANCIA G, MOLINARI A, CRATERI P et al.: Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans. Infect. Immun. (1995) 63:280-288.
75. ARANCIA G, STRINGARO A, CRATERI P et al.: Interaction between human interleukin-2-activated natural killer cells and heat-killed germ tube forms of Candida albicans. Cell. Immunol. (1998) 186:28-38. (Pubitemid 28285345)
76. GREENFIELD RA, ABRAMS VL, CRAWFORD DL, KUHLS TL: Effect of abrogation of natural killer cell activity on the course of candidiasis induced by intraperitoneal administration and gastrointestinal candidiasis in mice with severe combined immunodeficiency. Infect. Immun. (1993) 61:2520-2525. (Pubitemid 23159244)
77. ALGARRA I, ORTEGA E, SERRANO MJ, ALVAREZ DC, GAFORIO JJ: Suppression of splenic macrophage Candida albicans phagocytosis following in vivo depletion of natural killer cells in immunocompetent BALB/c mice and T-cell-deficient nude mice. FEMS Immunol. Med. Microbiol. (2002) 33:159-163. (Pubitemid 34756561)
78. MURCIANO C, VILLAMON E, O'CONNOR JE, GOZALBO D, GIL ML: Killed Candida albicans yeasts and hyphae inhibit gamma interferon release by murine natural killer cells. Infect. Immun. (2006) 74:1403-1406. (Pubitemid 43185583)
79. ZHANG MX, CUTLER JE, HAN Y, KOZEL TR: Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans. Infect. Immun. (1998) 66:6027-6029. (Pubitemid 28531871)
80. KOZEL TR, WEINHOLD LC, LUPAN DM: Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect. Immun. (1996) 64:3360-3368. (Pubitemid 26256188)
81. NETH O, JACK DL, DODDS AW et al.: Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. (2000) 68:688-693. (Pubitemid 30056524)
82. LILLEGARD JB, SIM RB, THORKILDSON P, GATES MA, KOZELTR: Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J. Infect. Dis. (2006) 193:1589-1597. (Pubitemid 43794589)
83. LEE SJ, GONZALEZ-ASEGUINOLAZA G, NUSSENZWEIG MC: Disseminated candidiasis and hepatic malarial infection in mannose-binding-lectin-A-deficient mice. Mol. Cell Biol. (2002) 22:8199-8203. (Pubitemid 35304053)
84. NETEA MG, CURFS JH, DEMACKER PN et al.: Infusion of lipoproteins into volunteers enhances the growth of Candida albicans. Clin. Infect. Dis. (1999) 28:1148-1151. (Pubitemid 29203554)
85. NETEA MG, DEMACKER PN, DE BONT N et al.: Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice. Infect. Immun. (1997) 65:2663-2667. (Pubitemid 27264092)
86. D'ANGIO R, QUERCIA RA, TREIBER NK, MCLAUGHLIN JC, KLIMEK JJ: The growth of microorganisms in total parenteral nutrition admixtures. J. Parenter. Enteral. Nutr. (1987) 11:394-397. (Pubitemid 17099991)
87. MURTHY AR, LEHRER RI, HARWIG SS, MIYASAKI KT: In vitro candidastatic properties of the human neutrophil calprotectin complex. J. Immunol. (1993) 151:6291-6301. (Pubitemid 23340375)
88. DE BONT N, NETEA MG, DEMACKER PN et al.: Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur. J. Clin. Invest. (2000) 30:818-822. (Pubitemid 30690627)
89. VONK AG, DE BONT N, NETEA MG et al.: Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Med. Mycol. (2004) 42:341-348. (Pubitemid 39207172)
90. MOURAD S, FRIEDMAN H: Pathogenicity of Candida. J. Bacteriol. (1961) 81:550-556.
91. MOURAD S, FRIEDMAN L: Passive immunization of mice against Candida albicans. Sabouraudia (1968) 6:103-105.
92. CARROW EW, HECTOR RF, DOMER JE: Immunodeficient CBA/N mice respond effectively to Candida albicans. Clin. Immunol. Immunopathol. (1984) 33:371-380. (Pubitemid 15184243)
93. JENSEN J, WARNER T, BALISH E: Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: role of polymorphonuclear leukocytes and macrophages. J. Infect. Dis. (1993) 167:912-919. (Pubitemid 23088262)
94. HAN Y, CUTLER JE: Antibody response that protects against disseminated candidiasis. Infect. Immun. (1995) 63:2714-2719.
95. HAN Y, RIESSELMAN MH, CUTLER JE: Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. (2000) 68:1649-1654. (Pubitemid 30108568)
96. ZHANG MX, BOHLMAN MC, ITATANI C et al.: Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. (2006) 74:362-369. (Pubitemid 43023092)
97. CAESAR TONTHAT TC, CUTLER JE: A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect. Immun. (1997) 65:5354-5357. (Pubitemid 27513594)
98. CUTLER JE: Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. (2005) 5:383-392. (Pubitemid 40846919)
99. MATTHEWS RC, BURNIE JP: Human recombinant antibody to HSP90: a natural partner in combination therapy. Curr. Mol. Med. (2005) 5:403-411. (Pubitemid 40846921)
100. VILANOVA M, TEIXEIRA L, CARAMALHO I et al.: Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology (2004) 111:334-342. (Pubitemid 38365757)
101. TOROSANTUCCI A, BROMURO C, CHIANI P et al.: A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. (2005) 202:597-606. (Pubitemid 41258184)
102. MONTAGNOLI C, BOZZA S, BACCI A et al.: A role for antibodies in the generation of memory antifungal immunity. Eur. J. Immunol. (2003) 33:1193-1204. (Pubitemid 36609137)
103. ROMANI L, MONTAGNOLI C, BOZZA S et al.: The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. Int. Immunol. (2004) 16:149-161. (Pubitemid 38054636)
104. TRINCHIERI G: Role of interleukin-12 in human Th1 response. Chem. Immunol. (1996) 63:14-29. (Pubitemid 26091841)
105. ROMANI L, MENCACCI A, GROHMANN U et al.: Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med. (1992) 176:19-25.
106. ROMANI L, PUCCETTI P, MENCACCI A et al.: Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J. Immunol. (1994) 152:3514-3521. (Pubitemid 24098048)
107. VAZQUEZ-TORRES A, JONES-CARSON J, WAGNER RD, WARNER T, BALISH E: Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect. Immun. (1999) 67:670-674. (Pubitemid 29059203)
108. MENCACCI A, DEL SERO G, CENCI E et al.: Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J. Exp. Med. (1998) 187:307-317. (Pubitemid 28080060)
109. MENCACCI A, CENCI E, DEL SERO G et al.: IL-10 is required for development of protective Th1 responses in IL-12-deficient mice upon Candida albicans infection. J. Immunol. (1998) 161:6228-6237. (Pubitemid 28535996)
110. SAKAGUCHI S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 101:455-458.
111. SHEVACH EM: Certified professionals: CD4(+)CD25(+) suppressor T cells. J. Exp. Med. (2001) 193:F41-F46.
112. RONCAROLO MG, LEVINGS MK: The role of different subsets of T regulatory cells in controlling autoimmunity. Curr. Opin. Immunol. (2000) 12:676-683. (Pubitemid 30847893)
113. COFFMAN RL, VARKILA K, SCOTT P, CHATELAIN R: Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol. Rev. (1991) 123:189-207.
114. MOORE KW, DE WAAL MR, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. (2001) 19:683-765. (Pubitemid 32368050)
115. HOSKEN NA, SHIBUYA K, HEATH AW, MURPHY KM, O'GARRA A: The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. (1995) 182:1579-1584.
116. CUTLER JE: Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J. Reticuloendothel. Soc. (1976) 19:121-124.
117. JONES-CARSON J, VAZQUEZ-TORRES A, WARNER T, BALISH E: Disparate requirement for T cells in resistance to mucosal and acute systemic candidiasis. Infect. Immun. (2000) 68:2363-2365. (Pubitemid 30164879)
118. MENCACCI A, SPACCAPELO R, DEL SERO G et al.: CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect. Immun. (1996) 64:4907-4914. (Pubitemid 26403940)
119. SPACCAPELO R, ROMANI L, TONNETTI L et al.: TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. (1995) 155:1349-1360.
120. KULLBERG BJ, VAN 'T WOUT JW, VAN FURTH R: Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect. Immun. (1990) 58:3319-3324. (Pubitemid 20293442)
121. VAN'T WOUT JW, VAN DER MEER JW, BARZA M, DINARELLO CA: Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur. J. Immunol. (1988) 18:1143-1146. (Pubitemid 18192203)
122. STUYT RJ, NETEA MG, VAN KRIEKEN JH, VAN DER MEER JW, KULLBERG BJ: Recombinant interleukin-18 protects against disseminated Candida albicans infection in mice. J. Infect. Dis. (2004) 189:1524-1527. • First study showing that recombinant IL-18 improves the outcome of disseminated candidiasis in immunocompetent mice and may prove useful as adjuvant immunotherapy of fungal infections.
123. NETEA MG, VAN TITS LJ, CURFS JH et al.: Increased susceptibility of TNF-alpha lymphotoxin-alpha double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J. Immunol. (1999) 163:1498-1505. (Pubitemid 29352772)
124. NETEA MG, BROUWER AE, HOOGENDOORN EH et al.: Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin. Infect. Dis. (2004) 39:e83-e87.
125. KULLBERG BJ, OUDE LASHOF AM, NETEA MG: Design of efficacy trials of cytokines in combination with antifungal drugs. Clin. Infect. Dis. (2004) 39(Suppl. 4):S218-S223. • Study providing an immunological explanation for the beneficial effect of IFN-γ in patients with invasive mycosis.
126. KULLBERG BJ, NETEA MG, CURFS JH et al.: Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J. Infect. Dis. (1998) 177:175-181. (Pubitemid 28030449)
127. VAN SPRIEL AB, VAN DEN HERIK-OUDIJK IE, VAN DE WINKEL JG: A single injection of polyethylene-glycol granulocyte colony-stimulating factor strongly prolongs survival of mice with systemic candidiasis. Cytokine (2000) 12:666-670. (Pubitemid 30453495)
128. KULLBERG BJ, VANDEWOUDE K, HERBRECHT R, JACOBS F, KUJATH P: A double-blind, randomized, placebo-controlled Phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington DC, USA (1998):479.
129. MENCACCI A, TOROSANTUCCI A, SPACCAPELO R et al.: A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect. Immun. (1994) 62:5353-5360. (Pubitemid 24364974)
130. HAN Y, ULRICH MA, CUTLER JE: Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. (1999) 179:1477-1484. (Pubitemid 29246598)
131. MONTAGNOLI C, SANDINI S, BACCI A, ROMANI L, LA VALLE R: Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med. Mycol. (2004) 42:319-324. (Pubitemid 39207169)
132. IBRAHIM AS, SPELLBERG BJ, AVENISSIAN V et al.: Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. (2005) 73:999-1005. (Pubitemid 40165760)
133. BROMURO C, TOROSANTUCCI A, CHIANI P et al.: Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. (2002) 70:5462-5470. (Pubitemid 35050979)
134. IWASAKI A, MEDZHITOV R: Toll-like receptor control of the adaptive immune responses. Nat. Immunol. (2004) 5:987-995. (Pubitemid 41057715)
135. VILLAMON E, GOZALBO D, ROIG P et al.: Toll-like receptor 2 is dispensable for acquired host immune resistance to Candida albicans in a murine model of disseminated candidiasis. Microbes Infect. (2004) 6:542-548. (Pubitemid 38680595)
136. BELLOCCHIO S, MONTAGNOLI C, BOZZA S et al.: The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J. Immunol. (2004) 172:3059-3069. (Pubitemid 38263695)
137. LIU L, KANG K, TAKAHARA M, COOPER KD, GHANNOUM MA: Hyphae and yeasts of Candida albicans differentially regulate interleukin-12 production by human blood monocytes: inhibitory role of C. albicans germination. Infect. Immun. (2001) 69:4695-4697. (Pubitemid 32574476)